Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.

ABSTRACT:

Importance

The head-to-head comparative effectiveness and safety of individual glucagon-like peptide-1 receptor agonists (GLP-1RAs) are not well understood.

Objective

To compare risks of kidney, cardiovascular, and death outcomes among patients with type 2 diabetes initiating GLP-1RAs in the Department of Veterans Affairs (VA) health system.

Design, setting, and participants

This comparative effectiveness study used an active-comparator, new-user target trial-emulation design with national data linked among the VA, Medicare, and US Renal Data System. Participants were GLP-1RA-naive veterans with type 2 diabetes and without end-stage kidney disease treated with metformin who started liraglutide, semaglutide, or dulaglutide between January 1, 2018, and December 31, 2021

SUBMITTER: Derington CG 

PROVIDER: S-EPMC12519307 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature